The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | MUK Nine b update: Dara-CVRd induction plus dara-VRd consolidation for ultra-high risk NDMM and pPCL
Martin Kaiser, MD, FRCP, FRCPath, The Royal Marsden NHS Foundation Trust, London, UK, gives an update on the final results of the MUK Nine b trial (NCT03188172) in patients with ultra-high risk newly diagnosed multiple myeloma (NDMM) and primary plasma cell leukemia (pPCL). Patients enrolled in MUK Nine b received intensified induction therapy with dara-CVRd (daratumumab (dara) plus cyclophosphamide (C), bortezomib (V), lenalidomide (R) and dexamethasone (d)), followed by V-augmented autologous stem cell transplantation (ASCT) and dara-based consolidation therapy. Outcomes were compared to a ‘digital comparator arm’ that used molecularly matched patients from the near-concurrent NCRI Myeloma XI/XI+ trial (NCT01554852) who were treated with CRd or carfilzomib-CRd (KCRd) induction, ASCT, and R maintenance or observation. After a median follow-up of 27.1 months, the median progression-free survival (PFS) was not reached in MUK Nine b patients. The study showed that at 18 months, PFS was higher in patients from the MUK Nine b study compared to Myeloma XI patients. The difference between trial treatments increased over time, suggesting particular efficacy of dara-VRd in maintaining responses post ASCT. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
